BP-1002

N/A

Report date: 2024/04/23 17:57:41
NME

Base Information

Drug NameBP-1002
Drug Alias NameLiposomal Bcl-2Liposomal Bcl2 antisenseL-Bcl-2 antisense oligonucleotideBP-1002BP-100-1.02
ClassificationSmall molecules > Nucleosides and nucleotide derivtives > Oligonucleotide > Oligonucleotide antisense
Mechanisms of ActionApoptosis regulator Bcl-2 inhibitorsRNA interference
TargetsApoptosis regulator Bcl-2
Therapy Area/IndicationsWaldenstrom MacroglobulinemiaLymphoma, T-Cell, PeripheralLymphoma, T-Cell, Cutaneous +[10] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaN/A
Originator CompaniesThe University Of Texas MD Anderson Cancer Center
China Registration ClassN/A

Develop Information

Active CompaniesBio-Path Holdings Inc
Inactive CompaniesN/A
Active IndicationsWaldenstrom MacroglobulinemiaLymphoma, T-Cell, PeripheralLymphoma, T-Cell, Cutaneous +[10] 
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A